An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype.

1. The study of the CYP2D genotype and phenotype of a Caucasian family revealed that a XbaI-9 kb allele was associated with the poor metabolizer phenotype. 2. A Polymerase Chain Reaction (PCR)-based assay showed that the previously described mutations D6A and D6B are not associated with the XbaI-9 kb allele. 3. To explore the molecular basis of the poor metabolizer phenotype associated with the XbaI-9 kb allele, complete sequencing of the nine exons and intron-exon boundaries of the CYP2D6 gene was undertaken after amplification by PCR. 4. All the exons were successfully amplified using CYP2D6 gene-specific primers except exon 1 which required a combination of CYP2D7 gene-specific 5' primer and a CYP2D6 gene-specific 3' primer. 5. Sequence data derived from this amplified product revealed that the XbaI-9 kb allele corresponds to a novel rearrangement of the locus. This involved a deletion of an approximately 20 kilobase (kb) DNA segment generating a hybrid 5' CYP2D7/CYP2D6 3' gene. 6. The chimeric gene is non-functional presumably due to an insertion in exon 1 (characteristic of the exon 1 of the CYP2D7 gene) which causes a shift in the reading frame with premature termination of translation.

[1]  S P Bryant,et al.  Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis. , 1993, Genomics.

[2]  J. S. Miles,et al.  Identification of the primary gene defect at the cytochrome P450 CYP2D locus , 1990, Nature.

[3]  R. Skoda,et al.  The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. , 1989, American journal of human genetics.

[4]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[5]  U. Meyer,et al.  Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. , 1990, The Journal of biological chemistry.

[6]  U. Meyer,et al.  The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. , 1990, American journal of human genetics.

[7]  U. Meyer,et al.  Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. , 1992, Genomics.

[8]  M. Eichelbaum,et al.  Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. , 1991, American journal of human genetics.

[9]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Nebert,et al.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.

[11]  R. Skoda,et al.  Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Idle,et al.  Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. , 1991, Pharmacogenetics.

[13]  J. Idle,et al.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. , 1980, Journal of medical genetics.

[14]  M. Relling,et al.  Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. , 1994, Human molecular genetics.

[15]  D. Nebert,et al.  Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. , 1988, Genomics.

[16]  M. Galteau,et al.  Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population. , 1993, British journal of clinical pharmacology.